Hazardous Drug Sample Analysis
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- HT942726QE008
- Agency
- Not on record
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Aberdeen, Maryland, United States
- Points of contact
-
- Jennifer Bassett jennifer.s.bassett.civ@health.mil (301) 619-2268
- Jessica E. Greene jessica.e.greene9.civ@health.mil (301) 619-7433
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency, operating under the Department of War's Defense Centers for Public Health-Aberdeen (DCPH-A), is soliciting quotations for Hazardous Drug Sample Analysis (HDSA) services to provide backup laboratory capability for wipe/swab sample testing at Military Treatment Facilities and pharmacies. The contractor must analyze samples for the presence of six chemotherapy-related hazardous drugs (5-Fluorouracil, Methotrexate, Ifosfamide, Cyclophosphamide Monohydrate, Doxorubicin Hydrochloride, and Paclitaxel) in any combination, in compliance with USP 800 and TB-MED 515 regulatory mandates. Key requirements include maintaining ISO/IEC 17025 accreditation, meeting turnaround times of 15 calendar days for standard priority and 8 calendar days for high priority samples, providing a Quality Control Plan, and submitting weekly status reports and monthly financial tracking. The government will collect all samples and provide testing wipes, making this a laboratory-only contract with the contractor responsible for all facilities, equipment, and sample disposal. Evaluation will be conducted using a Best Value Tradeoff methodology, assessing technical capability and approach, past performance relevancy and confidence, and price for fairness and reasonableness. The offer due date is April 24, 2026 at 11:00 AM Eastern Standard Time, with questions required by April 20, 2026 at 1:00 PM Eastern.
This solicitation is designated as a Women-Owned Small Business (WOSB) set-aside with no incumbent contractor identified in the available documents. The contract will be awarded on a firm fixed-price basis for 200 units of analysis services, with an anticipated annual workload of 100 to 225 analyses distributed across six service categories. The base performance period runs from May 1, 2026 through April 30, 2027, with an optional six-month extension available under FAR 52.217-8. Performance location is Aberdeen Proving Ground, Maryland, with the contract administered by the Defense Centers for Public Health Medical R&D Contracting Division. Late or deficient reporting will incur liquidated damages of 5 percent per day to a maximum of 100 percent of total invoice price, and contractors may subcontract with no more than three additional pre-approved laboratories meeting equivalent qualifications.
Notice text
2 versions
Update #2 · Latest ·
*******************************************************
***UPDATE - AMENDMENT #1***
The Purpose of this Amendment is to Provide Answers to Questions.
QUESTION #1 - The workload breakdown in the PWS (page 8) is structured simply by the number of drugs per sample batch, can you provide the specific drug types for each?
ANSWER #1 - A.) The PWS lists 6 possible Hazardous Drugs that a client could request. These are the only 6 requested at this time in any combination. They are: 5-Fluorouracil, Methotrexate, Ifosfamide, Cyclophosphamide Monohydrate, Doxorubicin Hydrochloride, and Paclitaxel.
B.) For Example, when a client wants "2" drugs reported, it could be a combination of any 2 of the above. One Client could request Methotrexate and Paclitaxel. Another Client could request 5-Fluorouracil and Ifosfamide. Both are only requesting "2" but the actual drugs are net set. Historically, 17 clients only wanted 1 drug reported for each sample. (each one though could have been unique)
QUESTION #2 - Is the Government or the Contractor to supply the wipes?
ANSWER #2 - The Government will supply the wipes.
QUESTION #3 - Please confirm that the government will be taking the samples and not the Contractor's technicians (i.e., the contract is 'lab only').
ANSWER #3 - The client (government) will collect the samples; nothing would be collected by the contract lab.
********************************************************
As part of the DCPH-A mission, the Lab Sciences (LS) Directorate requires the analysis of wipe/swab samples for the presence of hazardous drugs in support of pharmacies and Military Treatment Facilities (MTFs) within the Department of War (DoW). This analysis is mandated for the MTFs using Chemotherapy drugs to ensure their cleaning procedures are effective to ensure safety of the MTF staff and to avoid cross-contamination. The directives that mandate this semi-annual testing requirement are United Stated Pharmacopiea (USP) 800: Handling Hazardous Drugs and Technical Bulletin-Medical (TB-MED) 515: Occupational Health and Indutrial Hygiene Guidance for the Management, Use and Disposal of Hazardous Drugs. There is no acceptable level of occupational exposure to Hazardous Drugs. The LS Directorate of the DCPH-A is the only government laboratory to perform this hazardous drugs analysis as required. While LS does have the analytical capability to perform hazardous drugs analyses, as a sole source for this effort, there is a need to have back-up laboratory capability for instances of instrument down-time or over-capacity situations.
Objectives for this Requirement are as follows:
The Contractor shall perform analysis on wipe/swab samples provided by the Government for Hazardous Drugs contamination.
The Contractor shall perform the sample analysis within the stated turnaround time (TAT) identified in the Outsource Document and identified in the PWS.
The Contractor shall provide Quality wipe/swab analysis for various hazardous drugs as identified in this PWS in accordance with an accredited methodology.
The Contractor shall dispose of unused samples as prescribed by their quality manual/Standing Operating Procedures and return Government shipping containers.
The Contractor shall supply sampling media upon request.
The Contractor shall pay liquidated damages for late or deficient reporting as detailed in Section 5.of the PWS.
QUESTIONS are due by 20 April 2026 by 1pm Eastern Standard Time (EST)
QUOTATIONS are due by 24 April 2026 by 11am EST.
See the Performance Work Statement (PWS) for complete information regarding this effort.
Update #1 ·
As part of the DCPH-A mission, the Lab Sciences (LS) Directorate requires the analysis of wipe/swab samples for the presence of hazardous drugs in support of pharmacies and Military Treatment Facilities (MTFs) within the Department of War (DoW). This analysis is mandated for the MTFs using Chemotherapy drugs to ensure their cleaning procedures are effective to ensure safety of the MTF staff and to avoid cross-contamination. The directives that mandate this semi-annual testing requirement are United Stated Pharmacopiea (USP) 800: Handling Hazardous Drugs and Technical Bulletin-Medical (TB-MED) 515: Occupational Health and Indutrial Hygiene Guidance for the Management, Use and Disposal of Hazardous Drugs. There is no acceptable level of occupational exposure to Hazardous Drugs. The LS Directorate of the DCPH-A is the only government laboratory to perform this hazardous drugs analysis as required. While LS does have the analytical capability to perform hazardous drugs analyses, as a sole source for this effort, there is a need to have back-up laboratory capability for instances of instrument down-time or over-capacity situations.
Objectives for this Requirement are as follows:
The Contractor shall perform analysis on wipe/swab samples provided by the Government for Hazardous Drugs contamination.
The Contractor shall perform the sample analysis within the stated turnaround time (TAT) identified in the Outsource Document and identified in the PWS.
The Contractor shall provide Quality wipe/swab analysis for various hazardous drugs as identified in this PWS in accordance with an accredited methodology.
The Contractor shall dispose of unused samples as prescribed by their quality manual/Standing Operating Procedures and return Government shipping containers.
The Contractor shall supply sampling media upon request.
The Contractor shall pay liquidated damages for late or deficient reporting as detailed in Section 5.of the PWS.
QUESTIONS are due by 20 April 2026 by 1pm Eastern Standard Time (EST)
QUOTATIONS are due by 24 April 2026 by 11am EST.
See the Performance Work Statement (PWS) for complete information regarding this effort.
Attachments
| File | Type | Posted |
|---|---|---|
| HT9427-26-Q-E008-0001.pdf | ||
| Solicitation - HT942726QE008.pdf | ||
| Solicitation Attachment 2 - Quality Assurance Surveillance Plan_HDSA.pdf | ||
| Solicitation Attachment 1 - Performance Work Statement_HDSA.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Hazardous Drug Sample Analysis | Award Notice | |
| Hazardous Drug Sample Analysis | Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity